Previous 10 | Next 10 |
CRISPR Therapeutics ( CRSP ) has been on my watchlist for a couple of years but the stars never aligned for me to pull the trigger on a buy. Due to some recent updates, I am moving CRSP up to the top of my year-end shopping list and will be stalking an entry point in the coming weeks or months...
The bankers priced Vir Biotechnology (NASDAQ: VIR) at $20 a share for its IPO on Friday. There was no demand for the name. The stock opened at $16.20 a share and proceeded to drop to $14.02 a share by the end of the day. It was almost a 30% loss for early investors. Prior to the IPO, Arch V...
bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including haemophilia. During the three-year research collaboratio...
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed William R. Sellers, M.D. to its Board of Directors. “I’m excited to welcome Bill to the Board to help navigate an important stage in bluebird’s evolution,” said Nick Leschly, chief bluebi...
Introduction Alexandria Real Estate Equities ( ARE ) is able to deliver faster FFO growth than other Health Care REITs through portfolio concentration in specialized office and laboratory properties in top US technology and life science markets. Rent roll-ups keep same property NOI growing a...
On September 18th, bluebird bio ( BLUE ) announced updated results from their Lenti-D gene therapy studies for cerebral adrenoleukodystrophy ((CALD)) patients. The Phase II/III Starbeam study "ALD-102" is measuring the safety and efficacy of Lenti-D in boys aged 17 and under that suffer from...
Updated results from a Phase 2/3 clinical trial, Starbeam , evaluating bluebird bio's ( BLUE -1.6% ) gene therapy Lenti-D in patients with a rare severe inherited disorder called cerebral adrenoleukodystrophy (CALD) showed a sustained treatment effect. The data were presented at the ...
Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of Follow-up bluebird bio, Inc. (Nasdaq: BLUE) today announced updated r...
Shares of bluebird bio (NASDAQ: BLUE) sank more than 21% last month, according to data provided by S&P Global Market Intelligence . The biopharma announced second-quarter 2019 operating results, and although there wasn't much for the clinical-stage company to report, investors are begin...
Today, we want to share our analysis of Bellicum Pharmaceuticals ( BLCM ) with you. Over the last year, its stock largely fluctuated, falling from ~ $7 in September 2018 to $0.78 in August 2019. Recently, the company’s stock price grew by more than 20% after Baker Bros. disclosed its ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...